GeoVax Labs (GOVX) S-1 31 May 17 2017 Q1 IPO registration Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2017	May 25, 2017
Document Information [Line Items]
Entity Registrant Name	GeoVax Labs, Inc.
Entity Central Index Key	832,489
Trading Symbol	govx
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		60,551,900
Document Type	S1
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 166,749	$ 454,030
Grant funds receivable	21,514	28,074
Prepaid expenses and other current assets	52,124	62,275
Total current assets	240,387	544,379
Property and equipment, net	52,280	54,828
Deposits	11,010	11,010
Total assets	303,677	610,217
Current liabilities:
Accounts payable	150,912	75,607
Accrued expenses	396,989	294,240
Total current liabilities	547,901	369,847
Commitments
Stockholders’ equity (deficiency):
Common stock, $.001 par value:	56,219	55,235
Additional paid-in capital	34,977,726	34,914,963
Accumulated deficit	(36,294,969)	(35,746,628)
Total stockholders’ equity (deficiency)	(244,224)	240,370
Total liabilities and stockholders’ equity (deficiency)	303,677	610,217
Series B Convertible Preferred Stock [Member]
Stockholders’ equity (deficiency):
Convertible Preferred Stock	76,095	76,095
Series C Convertible Preferred Stock [Member]
Stockholders’ equity (deficiency):
Convertible Preferred Stock	$ 940,705	$ 940,705

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2017	Dec. 31, 2016	Jun. 14, 2016	Jun. 13, 2016	Dec. 31, 2015	Feb. 28, 2015
Preferred Stock, shares Authorized (in shares)	10,000,000	10,000,000			10,000,000
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01			$ 0.01
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001			$ 0.001
Common stock, shares authorized (in shares)	300,000,000	300,000,000	300,000,000	150,000,000	150,000,000
Common stock, shares issued (in shares)	56,218,567	55,235,233			31,950,813
Common stock, shares outstanding (in shares)	56,218,567	55,235,233			31,950,813
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000			$ 1,000
Preferred stock, shares issued (in shares)	100	100			100
Preferred stock, shares outstanding (in shares)	100	100			100
Series C Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000			$ 1,000	$ 1,000
Preferred stock, shares issued (in shares)	2,868	2,868			3,000
Preferred stock, shares outstanding (in shares)	2,868	2,868			3,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Grant revenues	$ 295,735	$ 47,600	$ 828,918	$ 428,081	$ 882,956
Operating expenses:
Research and development	551,795	438,004	1,970,859	1,693,102	1,812,969
General and administrative	292,667	906,505	2,131,426	1,429,731	1,807,605
Total operating expenses	844,462	1,344,509	4,102,285	3,122,833	3,620,574
Loss from operations	(548,727)	(1,296,909)	(3,273,367)	(2,694,752)	(2,737,618)
Other income:
Interest income	386	630	1,666	5,465	4,063
Total other income	386	630	1,666	5,465	4,063
Net loss	$ (548,341)	$ (1,296,279)	$ (3,271,701)	$ (2,689,287)	$ (2,733,555)
Basic and diluted:
Loss per common share (in dollars per share)	$ (0.01)	$ (0.04)	$ (0.08)	$ (0.08)	$ (0.10)
Weighted average shares outstanding (in shares)	55,350,974	34,599,625	41,516,514	31,950,813	26,645,140

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net loss	$ (548,341)	$ (1,296,279)	$ (3,271,701)	$ (2,689,287)	$ (2,733,555)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	6,898	7,195	28,780	28,935	69,037
Stock-based compensation expense	14,580	483,485	967,667	67,905	479,103
Changes in assets and liabilities:
Grant funds receivable	6,560	119,978	91,904	(40,637)	61,568
Prepaid expenses and other current assets	10,151	17,102	(5,626)	(12,146)	(934)
Accounts payable and accrued expenses	178,054	39,455	242,857	(60,033)	(125,326)
Total adjustments	216,243	667,215	1,325,582	(15,976)	483,448
Net cash used in operating activities	(332,098)	(629,064)	(1,946,119)	(2,705,263)	(2,250,107)
Cash flows from investing activities:
Purchase of property and equipment	(4,350)			(15,850)	(35,503)
Net cash used in investing activities	(4,350)			(15,850)	(35,503)
Cash flows from financing activities:
Proceeds from sale of common stock	49,167	238,198	1,339,801		873,400
Net cash provided by financing activities	49,167	238,198	1,339,801	2,679,810	873,400
Net decrease in cash and cash equivalents	(287,281)	(390,866)	(606,318)	(41,303)	(1,412,210)
Cash and cash equivalents at beginning of period	454,030	1,060,348	1,060,348	1,101,651	2,513,861
Cash and cash equivalents at end of period	$ 166,749	$ 669,482	$ 454,030	$ 1,060,348	$ 1,101,651

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - Series C Convertible Preferred Stock [Member] - shares	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Convertible preferred stock (in shares)	132
Common stock conversion (in shares)	1,400,000	1,400,000	0	0

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 454,030	$ 1,060,348
Grant funds receivable	28,074	119,978
Prepaid expenses and other current assets	62,275	56,649
Total current assets	544,379	1,236,975
Property and equipment, net	54,828	83,608
Other assets	11,010	11,010
Total assets	610,217	1,331,593
Current liabilities:
Accounts payable	75,607	100,935
Accrued expenses	294,240	26,055
Total current liabilities	369,847	126,990
Commitments
Stockholders’ equity (deficiency):
Common stock, $.001 par value:	55,235	31,951
Additional paid-in capital	34,914,963	32,587,543
Accumulated deficit	(35,746,628)	(32,474,927)
Total stockholders’ equity (deficiency)	240,370	1,204,603
Total liabilities and stockholders’ equity (deficiency)	610,217	1,331,593
Series B Convertible Preferred Stock [Member]
Stockholders’ equity (deficiency):
Convertible Preferred Stock	76,095	76,095
Series C Convertible Preferred Stock [Member]
Stockholders’ equity (deficiency):
Convertible Preferred Stock	$ 940,705	$ 983,941

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Mar. 31, 2017	Dec. 31, 2016	Jun. 14, 2016	Jun. 13, 2016	Dec. 31, 2015	Feb. 28, 2015
Preferred Stock, shares Authorized (in shares)	10,000,000	10,000,000			10,000,000
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01			$ 0.01
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001			$ 0.001
Common stock, shares authorized (in shares)	300,000,000	300,000,000	300,000,000	150,000,000	150,000,000
Common stock, shares issued (in shares)	56,218,567	55,235,233			31,950,813
Common stock, shares outstanding (in shares)	56,218,567	55,235,233			31,950,813
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000			$ 1,000
Preferred stock, shares issued (in shares)	100	100			100
Preferred stock, shares outstanding (in shares)	100	100			100
Series C Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000			$ 1,000	$ 1,000
Preferred stock, shares issued (in shares)	2,868	2,868			3,000
Preferred stock, shares outstanding (in shares)	2,868	2,868			3,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Grant revenues	$ 295,735	$ 47,600	$ 828,918	$ 428,081	$ 882,956
Operating expenses:
Research and development	551,795	438,004	1,970,859	1,693,102	1,812,969
General and administrative	292,667	906,505	2,131,426	1,429,731	1,807,605
Total operating expenses	844,462	1,344,509	4,102,285	3,122,833	3,620,574
Loss from operations	(548,727)	(1,296,909)	(3,273,367)	(2,694,752)	(2,737,618)
Other income:
Interest income	386	630	1,666	5,465	4,063
Total other income	386	630	1,666	5,465	4,063
Net loss	$ (548,341)	$ (1,296,279)	$ (3,271,701)	$ (2,689,287)	$ (2,733,555)
Basic and diluted:
Loss per common share (in dollars per share)	$ (0.01)	$ (0.04)	$ (0.08)	$ (0.08)	$ (0.10)
Weighted average shares outstanding (in shares)	55,350,974	34,599,625	41,516,514	31,950,813	26,645,140

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Series A Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Sale of common stock for cash upon warrant exercise				$ 3,176	$ 870,224		$ 873,400
Balance (in shares) at Dec. 31, 2013	71	1,650		23,765,180
Balance at Dec. 31, 2013	$ 60,586	$ 1,255,569		$ 23,765	28,239,392	(27,052,085)	2,527,227
Issuance of common stock for services (in shares)				378,205
Issuance of common stock for services				$ 378	99,622		100,000
Common stock conversion (in shares)	(71)	(1,550)		4,631,428
Conversion of preferred stock to common stock	$ (60,586)	$ (1,179,474)		$ 4,632	1,235,428
Sale of common stock for cash upon warrant exercise (in shares)				3,176,000
Balance at Dec. 31, 2014		$ 76,095		$ 31,951	30,823,769	(29,785,640)	1,146,175
Stock-based compensation expense					379,103		379,103
Net loss						(2,733,555)	(2,733,555)
Balance (in shares) at Dec. 31, 2014		100		31,950,813
Balance at Dec. 31, 2015		$ 76,095	$ 983,941	$ 31,951	32,587,543	(32,474,927)	1,204,603
Sale of convertible preferred stock for cash			$ 983,941		1,695,869		2,679,810
Sale of convertible preferred stock for cash (in shares)			3,000
Stock-based compensation expense					67,905		67,905
Net loss						(2,689,287)	(2,689,287)
Balance (in shares) at Dec. 31, 2015		100	3,000	31,950,813
Sale of common stock for cash upon warrant exercise				$ 21,884	1,317,917		1,339,801
Common stock conversion (in shares)			(132)	1,400,000
Conversion of preferred stock to common stock			$ (43,236)	$ 1,400	41,836
Sale of common stock for cash upon warrant exercise (in shares)				21,884,420
Balance at Dec. 31, 2016		$ 76,095	$ 940,705	$ 55,235	34,914,963	(35,746,628)	240,370
Stock-based compensation expense					967,667		967,667
Net loss						$ (3,271,701)	(3,271,701)
Balance (in shares) at Dec. 31, 2016		100	2,868	55,235,233
Balance at Mar. 31, 2017							(244,224)
Net loss							$ (548,341)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net loss	$ (3,271,701)	$ (2,689,287)	$ (2,733,555)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	28,780	28,935	69,037
Stock-based compensation expense, including common stock issued for services	967,667	67,905	479,103
Changes in assets and liabilities:
Grant funds receivable	91,904	(40,637)	61,568
Prepaid expenses and other current assets	(5,626)	(12,146)	(934)
Accounts payable and accrued expenses	242,857	(60,033)	(125,326)
Total adjustments	1,325,582	(15,976)	483,448
Net cash used in operating activities	(1,946,119)	(2,705,263)	(2,250,107)
Cash flows from investing activities:
Purchase of property and equipment		(15,850)	(35,503)
Net cash used in investing activities		(15,850)	(35,503)
Cash flows from financing activities:
Proceeds from sale of common stock	1,339,801		873,400
Proceeds from sale of preferred stock		2,679,810
Net cash provided by financing activities	1,339,801	2,679,810	873,400
Net decrease in cash and cash equivalents	(606,318)	(41,303)	(1,412,210)
Cash and cash equivalents at beginning of period	1,060,348	1,101,651	2,513,861
Cash and cash equivalents at end of period	$ 454,030	$ 1,060,348	$ 1,101,651

Consolidated Statements of Ca12

Consolidated Statements of Cash Flows (Parentheticals) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2014
Conversion from Series A Convertible Preferred Stock to Common Stock [Member]
Conversion of stock, shares issued (in shares)		202,857
Convertible preferred stock (in shares)		71
Conversion from Series C Convertible Preferred Stock to Common Stock [Member]
Conversion of stock, shares issued (in shares)	1,400,000
Convertible preferred stock (in shares)	132
Conversion from Series B Convertible Preferred Stock to Common Stock [Member]
Conversion of stock, shares issued (in shares)		4,428,571
Convertible preferred stock (in shares)		1,550

Note 1 - Description of Busines

Note 1 - Description of Business	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Notes to Financial Statements
Nature of Operations [Text Block]	1. GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing human vaccines using our novel vaccine platform. Our current development programs are focused on preventive vaccines against Human Immunodeficiency Virus (HIV), Zika Virus, hemorrhagic fever viruses, and malaria, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. We believe our technology and vaccine development expertise are well-suited for a variety of human infectious diseases and we intend to pursue further expansion of our product pipeline. Our vaccine development activities have been, and continue to be, financially supported by the U.S. government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials. We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may one GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in Smyrna, Georgia (metropolitan Atlanta area).	1. Description of Business GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing human vaccines using our novel vaccine platform. Our current development programs are focused vaccines against Human Immunodeficiency Virus (HIV), Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria. We are also evaluating the use of our vaccine platform in cancer immunotherapy, and for therapeutic use in chronic Hepatitis B infections. We believe our technology and vaccine development expertise are well-suited for a variety of human infectious diseases and we intend to pursue further expansion of our product pipeline. Our vaccine development activities have been, and continue to be, financially supported by the U.S. government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials. We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may one GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in Smyrna, Georgia (metropolitan Atlanta area).

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	3 Months Ended
	Mar. 31, 2017
Notes to Financial Statements
Basis of Accounting [Text Block]	2. The accompanying condensed consolidated financial statements at March 31, 2017 March 31, 2017 2016 not 10 December 31, 2016. not Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date of the financial statements. We are devoting substantially all of our present efforts to research and development of our vaccine candidates. We have funded our activities to date from government grants and clinical trial assistance, and from sales of our equity securities. We will continue to require substantial funds to continue these activities. We believe that our existing cash resources and government funding commitments will be sufficient to continue our planned operations into through the end of 2017. not may not

Note 3 - Significant Accounting

Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. We disclosed in Note 2 10 December 31, 2016 no 10 In March 2016, 2016 09, Improvements to Employee Share-Based Payment Accounting 2016 09” 718, 2016 09 2016 09 January 1, 2017; no There have been no three months ended March 31, 2017, 10 December 31, 2016,	2. Principles of Consolidation The accompanying consolidated financial statements include the accounts of GeoVax Labs, Inc. together with those of our wholly-owned subsidiary, GeoVax, Inc. All intercompany transactions have been eliminated in consolidation. Basis of Presentation The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date of these consolidated financial statements. We are devoting substantially all of our present efforts to research and development. We have funded our activities to date from government grants and clinical trial assistance, and from sales of our equity securities. We will continue to require substantial funds to continue our research and development activities. We believe that our existing cash resources and government funding commitments will be sufficient to continue our planned operations through the second 2017. not may not Use of Estimates The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may Cash and Cash Equivalents We consider all highly liquid investments with a maturity of three Fair Value of Financial Instruments and Concentration of Credit Risk Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized. We calculate depreciation using the straight-line method over the estimated useful lives of the assets which range from three five In February 2016, No. 2016 02, Leases 2016 02 2016 02 December 15, 2018, not 2016 02 may 2016 02. 2017 December 31, 2016, $151,993. Impairment of Long-Lived Assets We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not Accrued Expenses As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have not third Net Loss Per Share Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. Common share equivalents which could potentially dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, totaled approximately 93.9 90.3 6.6 December 31, 2016, 2015 2014, Revenue Recognition We recognize revenue in accordance with U.S. Securities and Exchange Commission (SEC) Staff Accounting Bulletin No. 101, Revenue Recognition in Financial Statements, No. 104, Revenue Recognition, 104 104 2016, 2015 2014, 5 In May 2014, 2014 09, Revenue from Contracts with Customers 2014 09 606. 2014 09 2017 2014 09 Research and Development Expense Research and development expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) salaries, benefits, and stock-based compensation for personnel, (ii) laboratory supplies and facility-related expenses to conduct development, (iii) fees paid to third-party service providers to perform, monitor and accumulate data related to our preclinical studies and clinical trials, (iv) costs related to sponsored research agreements, and (v) the costs to procure and manufacture materials used in clinical trials. These costs are charged to expense as incurred. Patent Costs Our expenditures relating to obtaining and protecting patents are charged to expense when incurred, and are included in general and administrative expense. Period to Period Comparisons Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not Income Taxes We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than not Stock-Based Compensation We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Compensation cost for stock options or warrants is estimated at the grant date based on each instrument’s fair value as calculated by the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note 9 In March 2016, 2016 09, Improvements to Employee Share-Based Payment Accounting 2016 09” 718, 2016 09 2016 09 2017 2016 09 Recent Accounting Pronouncements Except as discussed above, there have been no not

Note 4 - Basic and Diluted Loss

Note 4 - Basic and Diluted Loss Per Common Share	3 Months Ended
	Mar. 31, 2017
Notes to Financial Statements
Earnings Per Share [Text Block]	4. Basic net loss per share is computed using the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares and potentially dilutive common share equivalents outstanding during the period. Potentially dilutive common share equivalents consist of convertible preferred stock, stock options and stock purchase warrants. Common share equivalents which potentially could dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, as the effect would be anti-dilutive, totaled approximately 91.7 85.2 March 31, 2017 2016,

Note 5 - Property and Equipment

Note 5 - Property and Equipment	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and equipment as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of March 31, 2017 December 31, 2016: March 31, 2017 December 31, 2016 Laboratory equipment $ 530,306 $ 525,956 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 28,685 28,685 Total property and equipment 674,596 670,246 Accumulated depreciation and amortization (622,316 ) (615,418 ) Property and equipment, net $ 52,280 $ 54,828	3. Property and equipment as shown on the accompanying Consolidated Balance Sheets is composed of the following as of December 31, 2016 2015: 2016 2015 Laboratory equipment $ 525,956 $ 525,956 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 28,685 28,685 Total property and equipment 670,246 670,246 Accumulated depreciation and amortization (615,418 ) (586,638 ) Property and equipment, net $ 54,828 $ 83,608 Depreciation and leasehold amortization expense was $28,780, $28,935, $59,037 December 31, 2016, 2015 2014,

Note 6 - Accrued Expenses

Note 6 - Accrued Expenses	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. Accrued expenses as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of March 31, 2017 December 31, 2016: March 31, 2017 December 31, 2016 Accrued salaries $ 276,220 $ 201,170 Accrued directors’ fees 105,769 78,070 Other 15,000 15,000 Total accrued expenses $ 396,989 $ 294,240	4. Accrued expenses as shown on the accompanying Consolidated Balance Sheets is composed of the following as of December 31, 2016 2015: 2016 2015 Accrued compensation $ 201,170 $ 1,305 Accrued directors’ fees 78,070 - Other accrued expenses 15,000 24,750 Total accrued expenses $ 294,240 $ 26,055

Note 7 - Commitments

Note 7 - Commitments	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Notes to Financial Statements
Commitments Disclosure [Text Block]	7. Lease Agreement We lease approximately 8,400 December 31, 2017. March 31, 2017, $113,995 2017. Other Commitments In the normal course of business, we may March 31, 2017, $225,159 2017. 10	6 . Commitments Lease Agreements We lease approximately 8,400 December 31, 2017. December 31, 2016, 2015 2014 $149,288, $146,092, $117,084, $151,993 2017. Other Commitments In the normal course of business, we may December 31, 2016, $305,371 2017.

Note 8 - Stockholders' Equity

Note 8 - Stockholders' Equity	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	8. Common Stock Transactions During March 2017, 983,334 $49,167. Stock Options The following table presents a summary of our stock option transactions during the three months ended March 31, 2017: Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2016 3,499,475 $ 1.21 Granted -- -- Exercised -- -- Forfeited or expired (115,200 ) 17.75 Outstanding at March 31, 2017 3,384,275 $ 0.64 Exercisable at March 31, 2017 2,191,281 $ 1.69 Stock Purchase Warrants The following table presents a summary of stock purchase warrant transactions during the three months ended March 31, 2017: Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2016 32,751,578 $ 0.07 Granted -- -- Exercised (983,334 ) 0.05 Forfeited or expired (1,112,001 ) 0.57 Outstanding at March 31, 2017 30,656,243 $ 0.05 Exercisable at March 31, 2017 30,656,243 $ 0.05 Stock-Based Compensation Expense Stock-based compensation expense related to our stock option plans was $14,580 $13,686 March 31, 2017 2016, March 31, 2017, $117,404 2.3 In addition to the expense associated with our stock option plans, during the three-month period ended March 31, 2016 $469,799 Common Stock Reserved A summary of our common stock reserved for future issuance as of March 31, 2017 Series B Convertible Preferred Stock 285,714 Series C Convertible Preferred Stock 57,363,520 Common Stock Purchase Warrants 30,656,243 Equity Incentive Plans 4,590,300 Total 92,895,777	8. Common Stock Increase in Authorized Shares of Common Stock At our annual meeting of stockholders held on June 14, 2016, 150,000,000 300,000,000 June 14, 2016. Common Stock Transactions During July November 2014, 378,205 $100,000 9 During October 2014, 3,176,000 $873,400. At various times during 2016, 21,884,420 $1,339,801. We issued shares of our common stock related to conversions of our Series A, Series B and Series C Convertible Preferred Stock (see Note 7 2016 2015 2014 Conversions of Series A Preferred Stock -0- -0- 202,857 Conversions of Series B Preferred Stock -0- -0- 4,428,571 Conversions of Series C Preferred Stock 1,400,000 -0- -0- Stock Option Plans In 2006 2006 “2006 June 14, 2016, 2016 “2016 1,705,500 2006 3,000,000 2016 2016 2006 September 28, 2016, no may 2006 2016 . The exercise price for any option granted may not 110% ten three Certain information concerning our stock option plans as of December 31, 2016, Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (yrs) Aggregate Intrinsic Value Outstanding at December 31, 2015 1,705,500 $ 2.41 Granted 1,793,975 0.07 Exercised - - Forfeited or expired - - Outstanding at December 31, 2016 3,499,475 $ 1.21 8.2 $ -0- Exercisable at December 31, 2016 1,299,394 $ 3.12 5.5 $ -0- Stock Purchase Warrants As of December 31, 2016, Expiration Date Number of Shares Weighted Average Exercise Price January 16, 2017 45,000 1.00 January 31, 2017 567,001 1.00 March 21, 2017 1,483,334 0.05 February 27, 2020 30,656,243 0.05 Outstanding and exercisable at December 31, 2016 32,751,578 $ 0.07 The following table presents a summary of stock purchase warrant activity during the year ended December 31, 2016: Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2015 56,442,157 $ 0.14 Issued -- -- Exercised (21,884,420 ) 0.06 Forfeited or expired (1,806,159 ) 1.00 Outstanding and exercisable at December 31, 2016 32,751,578 $ 0.07 Common Stock Reserved A summary of common stock reserved for future issuance as of December 31, 2016 Stock Purchase Warrants 32,751,578 Stock Option Plans 4,705,500 Series B Convertible Preferred Stock 285,714 Series C Convertible Preferred Stock 57,363,520 Total 95,106,312

Note 9 - Income Taxes

Note 9 - Income Taxes	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Notes to Financial Statements
Income Tax Disclosure [Text Block]	9. Because of our historically significant net operating losses, we have not 382	11 . Income Taxes At December 31, 2016, $69.5 2019 2036. $892,000 2022 2036 No 382 may may Deferred income taxes reflect the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities included the following at December 31, 2016 2015: 2016 2015 Deferred tax assets: Net operating loss carryforward $ 24,689,298 $ 23,822,431 Research and development tax credit carryforward 892,231 893,797 Stock-based compensation expense 2,748,899 2,419,892 Depreciation 1,331 - Total deferred tax assets 28,331,759 27,136,120 Deferred tax liabilities Depreciation - (5,086 ) Total deferred tax liabilities - (5,086 ) Net deferred tax assets 28,331,759 27,131,034 Valuation allowance (28,331,759 ) (27,131,034 ) $ -0- $ -0- We have established a full valuation allowance equal to the amount of our net deferred tax assets due to uncertainties with respect to our ability to generate sufficient taxable income to realize these assets in the future. A reconciliation of the income tax benefit on losses at the U.S. federal statutory rate to the reported income tax expense is as follows: 2016 2015 2014 U.S. federal statutory rate applied to pretax loss $ (1,112,378 ) $ (936,936 ) $ (906,830 ) Permanent differences 2,012 2,914 1,734 Research and development credits 59,087 67,901 26,648 Change in valuation allowance 1,051,279 866,121 878,448 Reported income tax expense $ -0- $ -0- $ -0-

Note 10 - Government Grants and

Note 10 - Government Grants and Contracts	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Notes to Financial Statements
Government Grants and Contracts [Text Block]	10. We receive ongoing payments from government entities under our grants and contracts with the National Institute of Allergy and Infectious Diseases in support of our vaccine research and development efforts. We record revenue associated with government grants and contracts as the reimbursable costs are incurred. During the three-month periods ended March 31, 2017 2016, $295,735 $47,600, March 31, 2017, $867,911	5 . Government Grants and Contracts We record revenue associated with government grants and contracts as the related costs and expenses are incurred and such revenue is reported as Grant Revenue in the accompanying Consolidated Statements of Operations. Such revenues relate to grants and contracts from the NIH in support of our HIV vaccine development activities. During 2016, 2015, 2014, $828,918, $428,081, $882,956, December 31, 2016, $505,487 2017.

Note 11 - Subsequent Events

Note 11 - Subsequent Events	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Notes to Financial Statements
Subsequent Events [Text Block]	11. During April 2017, 2,500,000 $100,000. During May 2017, 1,000 $1,000,000. 66,666.67 66,666,667	12 . Subsequent Event During March 2017, 983,334 $49,167.

Note 1 - Description of Busin24

Note 1 - Description of Business	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Notes to Financial Statements
Nature of Operations [Text Block]	1. GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing human vaccines using our novel vaccine platform. Our current development programs are focused on preventive vaccines against Human Immunodeficiency Virus (HIV), Zika Virus, hemorrhagic fever viruses, and malaria, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. We believe our technology and vaccine development expertise are well-suited for a variety of human infectious diseases and we intend to pursue further expansion of our product pipeline. Our vaccine development activities have been, and continue to be, financially supported by the U.S. government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials. We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may one GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in Smyrna, Georgia (metropolitan Atlanta area).	1. Description of Business GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing human vaccines using our novel vaccine platform. Our current development programs are focused vaccines against Human Immunodeficiency Virus (HIV), Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria. We are also evaluating the use of our vaccine platform in cancer immunotherapy, and for therapeutic use in chronic Hepatitis B infections. We believe our technology and vaccine development expertise are well-suited for a variety of human infectious diseases and we intend to pursue further expansion of our product pipeline. Our vaccine development activities have been, and continue to be, financially supported by the U.S. government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials. We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may one GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in Smyrna, Georgia (metropolitan Atlanta area).

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. We disclosed in Note 2 10 December 31, 2016 no 10 In March 2016, 2016 09, Improvements to Employee Share-Based Payment Accounting 2016 09” 718, 2016 09 2016 09 January 1, 2017; no There have been no three months ended March 31, 2017, 10 December 31, 2016,	2. Principles of Consolidation The accompanying consolidated financial statements include the accounts of GeoVax Labs, Inc. together with those of our wholly-owned subsidiary, GeoVax, Inc. All intercompany transactions have been eliminated in consolidation. Basis of Presentation The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date of these consolidated financial statements. We are devoting substantially all of our present efforts to research and development. We have funded our activities to date from government grants and clinical trial assistance, and from sales of our equity securities. We will continue to require substantial funds to continue our research and development activities. We believe that our existing cash resources and government funding commitments will be sufficient to continue our planned operations through the second 2017. not may not Use of Estimates The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may Cash and Cash Equivalents We consider all highly liquid investments with a maturity of three Fair Value of Financial Instruments and Concentration of Credit Risk Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized. We calculate depreciation using the straight-line method over the estimated useful lives of the assets which range from three five In February 2016, No. 2016 02, Leases 2016 02 2016 02 December 15, 2018, not 2016 02 may 2016 02. 2017 December 31, 2016, $151,993. Impairment of Long-Lived Assets We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not Accrued Expenses As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have not third Net Loss Per Share Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. Common share equivalents which could potentially dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, totaled approximately 93.9 90.3 6.6 December 31, 2016, 2015 2014, Revenue Recognition We recognize revenue in accordance with U.S. Securities and Exchange Commission (SEC) Staff Accounting Bulletin No. 101, Revenue Recognition in Financial Statements, No. 104, Revenue Recognition, 104 104 2016, 2015 2014, 5 In May 2014, 2014 09, Revenue from Contracts with Customers 2014 09 606. 2014 09 2017 2014 09 Research and Development Expense Research and development expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) salaries, benefits, and stock-based compensation for personnel, (ii) laboratory supplies and facility-related expenses to conduct development, (iii) fees paid to third-party service providers to perform, monitor and accumulate data related to our preclinical studies and clinical trials, (iv) costs related to sponsored research agreements, and (v) the costs to procure and manufacture materials used in clinical trials. These costs are charged to expense as incurred. Patent Costs Our expenditures relating to obtaining and protecting patents are charged to expense when incurred, and are included in general and administrative expense. Period to Period Comparisons Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not Income Taxes We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than not Stock-Based Compensation We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Compensation cost for stock options or warrants is estimated at the grant date based on each instrument’s fair value as calculated by the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note 9 In March 2016, 2016 09, Improvements to Employee Share-Based Payment Accounting 2016 09” 718, 2016 09 2016 09 2017 2016 09 Recent Accounting Pronouncements Except as discussed above, there have been no not

Note 3 - Property and Equipment

Note 3 - Property and Equipment	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and equipment as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of March 31, 2017 December 31, 2016: March 31, 2017 December 31, 2016 Laboratory equipment $ 530,306 $ 525,956 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 28,685 28,685 Total property and equipment 674,596 670,246 Accumulated depreciation and amortization (622,316 ) (615,418 ) Property and equipment, net $ 52,280 $ 54,828	3. Property and equipment as shown on the accompanying Consolidated Balance Sheets is composed of the following as of December 31, 2016 2015: 2016 2015 Laboratory equipment $ 525,956 $ 525,956 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 28,685 28,685 Total property and equipment 670,246 670,246 Accumulated depreciation and amortization (615,418 ) (586,638 ) Property and equipment, net $ 54,828 $ 83,608 Depreciation and leasehold amortization expense was $28,780, $28,935, $59,037 December 31, 2016, 2015 2014,

Note 4 - Accrued Expenses

Note 4 - Accrued Expenses	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. Accrued expenses as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of March 31, 2017 December 31, 2016: March 31, 2017 December 31, 2016 Accrued salaries $ 276,220 $ 201,170 Accrued directors’ fees 105,769 78,070 Other 15,000 15,000 Total accrued expenses $ 396,989 $ 294,240	4. Accrued expenses as shown on the accompanying Consolidated Balance Sheets is composed of the following as of December 31, 2016 2015: 2016 2015 Accrued compensation $ 201,170 $ 1,305 Accrued directors’ fees 78,070 - Other accrued expenses 15,000 24,750 Total accrued expenses $ 294,240 $ 26,055

Note 5 - Government Grants and

Note 5 - Government Grants and Contracts	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Notes to Financial Statements
Government Grants and Contracts [Text Block]	10. We receive ongoing payments from government entities under our grants and contracts with the National Institute of Allergy and Infectious Diseases in support of our vaccine research and development efforts. We record revenue associated with government grants and contracts as the reimbursable costs are incurred. During the three-month periods ended March 31, 2017 2016, $295,735 $47,600, March 31, 2017, $867,911	5 . Government Grants and Contracts We record revenue associated with government grants and contracts as the related costs and expenses are incurred and such revenue is reported as Grant Revenue in the accompanying Consolidated Statements of Operations. Such revenues relate to grants and contracts from the NIH in support of our HIV vaccine development activities. During 2016, 2015, 2014, $828,918, $428,081, $882,956, December 31, 2016, $505,487 2017.

Note 6 - Commitements

Note 6 - Commitements	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Notes to Financial Statements
Commitments Disclosure [Text Block]	7. Lease Agreement We lease approximately 8,400 December 31, 2017. March 31, 2017, $113,995 2017. Other Commitments In the normal course of business, we may March 31, 2017, $225,159 2017. 10	6 . Commitments Lease Agreements We lease approximately 8,400 December 31, 2017. December 31, 2016, 2015 2014 $149,288, $146,092, $117,084, $151,993 2017. Other Commitments In the normal course of business, we may December 31, 2016, $305,371 2017.

Note 7 - Preferred Stock

Note 7 - Preferred Stock	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Preferred Stock [Text Block]	7 . Preferred Stock Series A Convertible Preferred Stock During 2014, 71 $1,000 202,857 December 31, 2016, no Series B Convertible Preferred Stock Our Series B Convertible Preferred Stock, $1,000 no not During 2014, 1,550 4,428,571 December 31, 2016, 100 Series B Preferred Stock outstanding, convertible at any time at the option of the holder into 285,714 Series C Convertible Preferred Stock In February 2015, 3,000 $1,000 51,333,331 $2,679,810. $1,695,869 $983,941 The Series C Preferred Stock has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series C Preferred Stock has no not The Series C Preferred Stock is convertible at any time at the option of the holders into shares of our common stock, and contains price adjustment provisions which may, 2016, 132 1,400,000 December 31, 2016, 2,868 Series C Preferred Stock outstanding, convertible into 57,363,520

Note 8 - Common Stock

Note 8 - Common Stock	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	8. Common Stock Transactions During March 2017, 983,334 $49,167. Stock Options The following table presents a summary of our stock option transactions during the three months ended March 31, 2017: Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2016 3,499,475 $ 1.21 Granted -- -- Exercised -- -- Forfeited or expired (115,200 ) 17.75 Outstanding at March 31, 2017 3,384,275 $ 0.64 Exercisable at March 31, 2017 2,191,281 $ 1.69 Stock Purchase Warrants The following table presents a summary of stock purchase warrant transactions during the three months ended March 31, 2017: Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2016 32,751,578 $ 0.07 Granted -- -- Exercised (983,334 ) 0.05 Forfeited or expired (1,112,001 ) 0.57 Outstanding at March 31, 2017 30,656,243 $ 0.05 Exercisable at March 31, 2017 30,656,243 $ 0.05 Stock-Based Compensation Expense Stock-based compensation expense related to our stock option plans was $14,580 $13,686 March 31, 2017 2016, March 31, 2017, $117,404 2.3 In addition to the expense associated with our stock option plans, during the three-month period ended March 31, 2016 $469,799 Common Stock Reserved A summary of our common stock reserved for future issuance as of March 31, 2017 Series B Convertible Preferred Stock 285,714 Series C Convertible Preferred Stock 57,363,520 Common Stock Purchase Warrants 30,656,243 Equity Incentive Plans 4,590,300 Total 92,895,777	8. Common Stock Increase in Authorized Shares of Common Stock At our annual meeting of stockholders held on June 14, 2016, 150,000,000 300,000,000 June 14, 2016. Common Stock Transactions During July November 2014, 378,205 $100,000 9 During October 2014, 3,176,000 $873,400. At various times during 2016, 21,884,420 $1,339,801. We issued shares of our common stock related to conversions of our Series A, Series B and Series C Convertible Preferred Stock (see Note 7 2016 2015 2014 Conversions of Series A Preferred Stock -0- -0- 202,857 Conversions of Series B Preferred Stock -0- -0- 4,428,571 Conversions of Series C Preferred Stock 1,400,000 -0- -0- Stock Option Plans In 2006 2006 “2006 June 14, 2016, 2016 “2016 1,705,500 2006 3,000,000 2016 2016 2006 September 28, 2016, no may 2006 2016 . The exercise price for any option granted may not 110% ten three Certain information concerning our stock option plans as of December 31, 2016, Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (yrs) Aggregate Intrinsic Value Outstanding at December 31, 2015 1,705,500 $ 2.41 Granted 1,793,975 0.07 Exercised - - Forfeited or expired - - Outstanding at December 31, 2016 3,499,475 $ 1.21 8.2 $ -0- Exercisable at December 31, 2016 1,299,394 $ 3.12 5.5 $ -0- Stock Purchase Warrants As of December 31, 2016, Expiration Date Number of Shares Weighted Average Exercise Price January 16, 2017 45,000 1.00 January 31, 2017 567,001 1.00 March 21, 2017 1,483,334 0.05 February 27, 2020 30,656,243 0.05 Outstanding and exercisable at December 31, 2016 32,751,578 $ 0.07 The following table presents a summary of stock purchase warrant activity during the year ended December 31, 2016: Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2015 56,442,157 $ 0.14 Issued -- -- Exercised (21,884,420 ) 0.06 Forfeited or expired (1,806,159 ) 1.00 Outstanding and exercisable at December 31, 2016 32,751,578 $ 0.07 Common Stock Reserved A summary of common stock reserved for future issuance as of December 31, 2016 Stock Purchase Warrants 32,751,578 Stock Option Plans 4,705,500 Series B Convertible Preferred Stock 285,714 Series C Convertible Preferred Stock 57,363,520 Total 95,106,312

Note 9 - Stock-based Compensati

Note 9 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	9. Stock-Based Compensation Stock Option Plans We use the Black-Scholes model for determining the grant date fair value of our stock option grants. This model utilizes certain information, such as the interest rate on a risk-free security with a term generally equivalent to the expected life of the option being valued and requires certain other assumptions, such as the expected amount of time an option will be outstanding until it is exercised or expired, to calculate the fair value of stock options granted. The significant assumptions we used in our fair value calculations were as follows: 2016 2015 2014 Weighted average risk-free interest rates 2.26 % 1.99 % 1.98 % Expected dividend yield 0.0 % 0.0 % 0.0 % Expected life of option (yrs 7.0 7.0 7.0 Expected volatility 88.72 % 91.43 % 94.88 % Stock-based compensation expense related to our stock option plans was $54,805, $67,905, $101,191 December 31, 2016, 2015 2014, three years ended December 31, 2016, 2016 2015 2014 General and administrative expense $ 31,191 $ 45,822 $ 69,057 Research and development expense 23,614 22,083 32,134 Total stock option expense $ 54,805 $ 67,905 $ 101,191 As of December 31, 2016, $132,032 2.5 Additional information concerning our stock options for the years ended December 31, 2016, 2015 2014 2016 2015 2014 Weighted average fair value of options granted $ 0.05 $ 0.09 $ 0.14 Intrinsic value of options exercised -0- -0- -0- Total fair value of options vested 54,757 66,622 97,707 Other Non-E mp loyee Stock-Based C ompensation We recorded general and administrative expense of $100,000 December 31, 2015 We recorded general and administrative expense of $912,862, 0 $277,912 December 31, 2016, 2015 2014,

Note 10 - Retirement Plan

Note 10 - Retirement Plan	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	10 . Retirement Plan We participate in a multi-employer defined contribution retirement plan (the “401k third 401k December 31, 2016, 2015 2014 401k $33,871, $40,296, $35,567,

Note 11 - Income Taxes

Note 11 - Income Taxes	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Notes to Financial Statements
Income Tax Disclosure [Text Block]	9. Because of our historically significant net operating losses, we have not 382	11 . Income Taxes At December 31, 2016, $69.5 2019 2036. $892,000 2022 2036 No 382 may may Deferred income taxes reflect the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities included the following at December 31, 2016 2015: 2016 2015 Deferred tax assets: Net operating loss carryforward $ 24,689,298 $ 23,822,431 Research and development tax credit carryforward 892,231 893,797 Stock-based compensation expense 2,748,899 2,419,892 Depreciation 1,331 - Total deferred tax assets 28,331,759 27,136,120 Deferred tax liabilities Depreciation - (5,086 ) Total deferred tax liabilities - (5,086 ) Net deferred tax assets 28,331,759 27,131,034 Valuation allowance (28,331,759 ) (27,131,034 ) $ -0- $ -0- We have established a full valuation allowance equal to the amount of our net deferred tax assets due to uncertainties with respect to our ability to generate sufficient taxable income to realize these assets in the future. A reconciliation of the income tax benefit on losses at the U.S. federal statutory rate to the reported income tax expense is as follows: 2016 2015 2014 U.S. federal statutory rate applied to pretax loss $ (1,112,378 ) $ (936,936 ) $ (906,830 ) Permanent differences 2,012 2,914 1,734 Research and development credits 59,087 67,901 26,648 Change in valuation allowance 1,051,279 866,121 878,448 Reported income tax expense $ -0- $ -0- $ -0-

Note 12 - Subsequent Event

Note 12 - Subsequent Event	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Notes to Financial Statements
Subsequent Events [Text Block]	11. During April 2017, 2,500,000 $100,000. During May 2017, 1,000 $1,000,000. 66,666.67 66,666,667	12 . Subsequent Event During March 2017, 983,334 $49,167.

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	GEOVAX LABS, INC. SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS For t he Years Ended December 31, 2016, 2015 2014 Additions Description Balance at Beginning Of Period Charged to Costs and Expenses Charged to Other Accounts (1) Deductions Balance at End Of Period Reserve Deducted in the Balance Sheet From the Asset to Which it Applies: Allowance for Deferred Tax Assets Year ended December 31, 2016 $ 27,131,034 $ 1,200,725 $ -0- $ -0- $ 28,331,759 Year ended December 31, 2015 26,021,943 1,109,091 -0- -0- 27,131,034 Year ended December 31, 2014 25,002,881 1,019,062 -0- -0- 26,021,943 ( 1 Deductions represent the effect of expiring NOL carryforwards from prior year.

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The accompanying consolidated financial statements include the accounts of GeoVax Labs, Inc. together with those of our wholly-owned subsidiary, GeoVax, Inc. All intercompany transactions have been eliminated in consolidation.
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date of these consolidated financial statements. We are devoting substantially all of our present efforts to research and development. We have funded our activities to date from government grants and clinical trial assistance, and from sales of our equity securities. We will continue to require substantial funds to continue our research and development activities. We believe that our existing cash resources and government funding commitments will be sufficient to continue our planned operations through the second 2017. not may not
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents We consider all highly liquid investments with a maturity of three
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments and Concentration of Credit Risk Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized. We calculate depreciation using the straight-line method over the estimated useful lives of the assets which range from three five In February 2016, No. 2016 02, Leases 2016 02 2016 02 December 15, 2018, not 2016 02 may 2016 02. 2017 December 31, 2016, $151,993.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not
Accrued Liabilities [Policy Text Block]	Accrued Expenses As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have not third
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. Common share equivalents which could potentially dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, totaled approximately 93.9 90.3 6.6 December 31, 2016, 2015 2014,
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition We recognize revenue in accordance with U.S. Securities and Exchange Commission (SEC) Staff Accounting Bulletin No. 101, Revenue Recognition in Financial Statements, No. 104, Revenue Recognition, 104 104 2016, 2015 2014, 5 In May 2014, 2014 09, Revenue from Contracts with Customers 2014 09 606. 2014 09 2017 2014 09
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expense Research and development expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) salaries, benefits, and stock-based compensation for personnel, (ii) laboratory supplies and facility-related expenses to conduct development, (iii) fees paid to third-party service providers to perform, monitor and accumulate data related to our preclinical studies and clinical trials, (iv) costs related to sponsored research agreements, and (v) the costs to procure and manufacture materials used in clinical trials. These costs are charged to expense as incurred.
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patent Costs Our expenditures relating to obtaining and protecting patents are charged to expense when incurred, and are included in general and administrative expense.
Reclassification, Policy [Policy Text Block]	Period to Period Comparisons Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not
Income Tax, Policy [Policy Text Block]	Income Taxes We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than not
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Compensation cost for stock options or warrants is estimated at the grant date based on each instrument’s fair value as calculated by the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note 9 In March 2016, 2016 09, Improvements to Employee Share-Based Payment Accounting 2016 09” 718, 2016 09 2016 09 2017 2016 09
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Except as discussed above, there have been no not

Note 5 - Property and Equipme38

Note 5 - Property and Equipment (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, 2017 December 31, 2016 Laboratory equipment $ 530,306 $ 525,956 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 28,685 28,685 Total property and equipment 674,596 670,246 Accumulated depreciation and amortization (622,316 ) (615,418 ) Property and equipment, net $ 52,280 $ 54,828	2016 2015 Laboratory equipment $ 525,956 $ 525,956 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 28,685 28,685 Total property and equipment 670,246 670,246 Accumulated depreciation and amortization (615,418 ) (586,638 ) Property and equipment, net $ 54,828 $ 83,608

Note 6 - Accrued Expenses (Tabl

Note 6 - Accrued Expenses (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	March 31, 2017 December 31, 2016 Accrued salaries $ 276,220 $ 201,170 Accrued directors’ fees 105,769 78,070 Other 15,000 15,000 Total accrued expenses $ 396,989 $ 294,240	2016 2015 Accrued compensation $ 201,170 $ 1,305 Accrued directors’ fees 78,070 - Other accrued expenses 15,000 24,750 Total accrued expenses $ 294,240 $ 26,055

Note 8 - Stockholders' Equity (

Note 8 - Stockholders' Equity (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Notes Tables
Share-based Compensation, Activity [Table Text Block]	Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2016 3,499,475 $ 1.21 Granted -- -- Exercised -- -- Forfeited or expired (115,200 ) 17.75 Outstanding at March 31, 2017 3,384,275 $ 0.64 Exercisable at March 31, 2017 2,191,281 $ 1.69	Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (yrs) Aggregate Intrinsic Value Outstanding at December 31, 2015 1,705,500 $ 2.41 Granted 1,793,975 0.07 Exercised - - Forfeited or expired - - Outstanding at December 31, 2016 3,499,475 $ 1.21 8.2 $ -0- Exercisable at December 31, 2016 1,299,394 $ 3.12 5.5 $ -0-
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2016 32,751,578 $ 0.07 Granted -- -- Exercised (983,334 ) 0.05 Forfeited or expired (1,112,001 ) 0.57 Outstanding at March 31, 2017 30,656,243 $ 0.05 Exercisable at March 31, 2017 30,656,243 $ 0.05	Expiration Date Number of Shares Weighted Average Exercise Price January 16, 2017 45,000 1.00 January 31, 2017 567,001 1.00 March 21, 2017 1,483,334 0.05 February 27, 2020 30,656,243 0.05 Outstanding and exercisable at December 31, 2016 32,751,578 $ 0.07
Schedule of Stock by Class [Table Text Block]	Series B Convertible Preferred Stock 285,714 Series C Convertible Preferred Stock 57,363,520 Common Stock Purchase Warrants 30,656,243 Equity Incentive Plans 4,590,300 Total 92,895,777	Stock Purchase Warrants 32,751,578 Stock Option Plans 4,705,500 Series B Convertible Preferred Stock 285,714 Series C Convertible Preferred Stock 57,363,520 Total 95,106,312

Note 3 - Property and Equipme41

Note 3 - Property and Equipment (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, 2017 December 31, 2016 Laboratory equipment $ 530,306 $ 525,956 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 28,685 28,685 Total property and equipment 674,596 670,246 Accumulated depreciation and amortization (622,316 ) (615,418 ) Property and equipment, net $ 52,280 $ 54,828	2016 2015 Laboratory equipment $ 525,956 $ 525,956 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 28,685 28,685 Total property and equipment 670,246 670,246 Accumulated depreciation and amortization (615,418 ) (586,638 ) Property and equipment, net $ 54,828 $ 83,608

Note 4 - Accrued Expenses (Tabl

Note 4 - Accrued Expenses (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	March 31, 2017 December 31, 2016 Accrued salaries $ 276,220 $ 201,170 Accrued directors’ fees 105,769 78,070 Other 15,000 15,000 Total accrued expenses $ 396,989 $ 294,240	2016 2015 Accrued compensation $ 201,170 $ 1,305 Accrued directors’ fees 78,070 - Other accrued expenses 15,000 24,750 Total accrued expenses $ 294,240 $ 26,055

Note 8 - Common Stock (Tables)

Note 8 - Common Stock (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Notes Tables
Schedule of Conversions of Convertible Preferred Stock [Table Text Block]		2016 2015 2014 Conversions of Series A Preferred Stock -0- -0- 202,857 Conversions of Series B Preferred Stock -0- -0- 4,428,571 Conversions of Series C Preferred Stock 1,400,000 -0- -0-
Share-based Compensation, Activity [Table Text Block]	Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2016 3,499,475 $ 1.21 Granted -- -- Exercised -- -- Forfeited or expired (115,200 ) 17.75 Outstanding at March 31, 2017 3,384,275 $ 0.64 Exercisable at March 31, 2017 2,191,281 $ 1.69	Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (yrs) Aggregate Intrinsic Value Outstanding at December 31, 2015 1,705,500 $ 2.41 Granted 1,793,975 0.07 Exercised - - Forfeited or expired - - Outstanding at December 31, 2016 3,499,475 $ 1.21 8.2 $ -0- Exercisable at December 31, 2016 1,299,394 $ 3.12 5.5 $ -0-
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2016 32,751,578 $ 0.07 Granted -- -- Exercised (983,334 ) 0.05 Forfeited or expired (1,112,001 ) 0.57 Outstanding at March 31, 2017 30,656,243 $ 0.05 Exercisable at March 31, 2017 30,656,243 $ 0.05	Expiration Date Number of Shares Weighted Average Exercise Price January 16, 2017 45,000 1.00 January 31, 2017 567,001 1.00 March 21, 2017 1,483,334 0.05 February 27, 2020 30,656,243 0.05 Outstanding and exercisable at December 31, 2016 32,751,578 $ 0.07
Schedule of Warrant Activity [Table Text Block]		Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2015 56,442,157 $ 0.14 Issued -- -- Exercised (21,884,420 ) 0.06 Forfeited or expired (1,806,159 ) 1.00 Outstanding and exercisable at December 31, 2016 32,751,578 $ 0.07
Schedule of Stock by Class [Table Text Block]	Series B Convertible Preferred Stock 285,714 Series C Convertible Preferred Stock 57,363,520 Common Stock Purchase Warrants 30,656,243 Equity Incentive Plans 4,590,300 Total 92,895,777	Stock Purchase Warrants 32,751,578 Stock Option Plans 4,705,500 Series B Convertible Preferred Stock 285,714 Series C Convertible Preferred Stock 57,363,520 Total 95,106,312

Note 9 - Stock-based Compensa44

Note 9 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2016 2015 2014 Weighted average risk-free interest rates 2.26 % 1.99 % 1.98 % Expected dividend yield 0.0 % 0.0 % 0.0 % Expected life of option (yrs 7.0 7.0 7.0 Expected volatility 88.72 % 91.43 % 94.88 %
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	2016 2015 2014 General and administrative expense $ 31,191 $ 45,822 $ 69,057 Research and development expense 23,614 22,083 32,134 Total stock option expense $ 54,805 $ 67,905 $ 101,191
Share-based Compensation, Stock Options, Activity [Table Text Block]	2016 2015 2014 Weighted average fair value of options granted $ 0.05 $ 0.09 $ 0.14 Intrinsic value of options exercised -0- -0- -0- Total fair value of options vested 54,757 66,622 97,707

Note 11 - Income Taxes (Tables)

Note 11 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2016 2015 Deferred tax assets: Net operating loss carryforward $ 24,689,298 $ 23,822,431 Research and development tax credit carryforward 892,231 893,797 Stock-based compensation expense 2,748,899 2,419,892 Depreciation 1,331 - Total deferred tax assets 28,331,759 27,136,120 Deferred tax liabilities Depreciation - (5,086 ) Total deferred tax liabilities - (5,086 ) Net deferred tax assets 28,331,759 27,131,034 Valuation allowance (28,331,759 ) (27,131,034 ) $ -0- $ -0-
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2016 2015 2014 U.S. federal statutory rate applied to pretax loss $ (1,112,378 ) $ (936,936 ) $ (906,830 ) Permanent differences 2,012 2,914 1,734 Research and development credits 59,087 67,901 26,648 Change in valuation allowance 1,051,279 866,121 878,448 Reported income tax expense $ -0- $ -0- $ -0-

Schedule II - Valuation and Q46

Schedule II - Valuation and Qualifying Accounts (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Summary of Valuation Allowance [Table Text Block]	Additions Description Balance at Beginning Of Period Charged to Costs and Expenses Charged to Other Accounts (1) Deductions Balance at End Of Period Reserve Deducted in the Balance Sheet From the Asset to Which it Applies: Allowance for Deferred Tax Assets Year ended December 31, 2016 $ 27,131,034 $ 1,200,725 $ -0- $ -0- $ 28,331,759 Year ended December 31, 2015 26,021,943 1,109,091 -0- -0- 27,131,034 Year ended December 31, 2014 25,002,881 1,019,062 -0- -0- 26,021,943

Note 4 - Basic and Diluted Lo47

Note 4 - Basic and Diluted Loss Per Common Share (Details Textual) - shares shares in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	91.7	85.2	93.9	90.3	6.6

Note 5 - Property and Equipme48

Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Property and equipment, gross	$ 674,596	$ 670,246	$ 670,246
Accumulated depreciation and amortization	(622,316)	(615,418)	(586,638)
Property and equipment, net	52,280	54,828	83,608
Laboratory Equipment [Member]
Property and equipment, gross	530,306	525,956	525,956
Leasehold Improvements [Member]
Property and equipment, gross	115,605	115,605	115,605
Other Furniture Fixtures And Equipment [Member]
Property and equipment, gross	$ 28,685	$ 28,685	$ 28,685

Note 6 - Accrued Expenses - Sch

Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accrued salaries	$ 276,220	$ 201,170	$ 1,305
Accrued directors’ fees	105,769	78,070
Other	15,000	15,000	24,750
Total accrued expenses	$ 396,989	$ 294,240	$ 26,055

Note 7 - Commitments (Details T

Note 7 - Commitments (Details Textual)	Mar. 31, 2017USD ($)ft²	Dec. 31, 2016USD ($)ft²
Area of Real Estate Property | ft²	8,400	8,400
Operating Leases, Future Minimum Payments Due	$ 113,995	$ 151,993
Unrecorded Unconditional Purchase Obligation	$ 225,159	$ 305,371

Note 8 - Stockholders' Equity51

Note 8 - Stockholders' Equity (Details Textual) - USD ($)	1 Months Ended		3 Months Ended		12 Months Ended
	Mar. 31, 2017	Oct. 31, 2014	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Stock Issued During Period, Shares, Warrants Exercised	983,334
Proceeds from Warrant Exercises	$ 49,167
General and Administrative Expense			$ 292,667	$ 906,505	$ 2,131,426	$ 1,429,731	$ 1,807,605
Expense Associated with Warrant Modifications [Member]
Stock Issued During Period, Shares, Warrants Exercised		3,176,000			21,884,420
Proceeds from Warrant Exercises		$ 873,400			$ 1,339,801
General and Administrative Expense				469,799	912,862	0	277,912
2006 Equity Incentive Plan [Member]
Allocated Share-based Compensation Expense			14,580	$ 13,686	54,805	$ 67,905	$ 101,191
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 117,404		$ 117,404		$ 132,032
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			2 years 109 days		2 years 182 days

Note 8 - Stockholders' Equity -

Note 8 - Stockholders' Equity - Activity of Stock Option Plan (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Outstanding, options (in shares)	3,499,475	1,705,500
Outstanding, weighted average exercise price, options (in dollars per share)	$ 1.21	$ 2.41
Granted, options (in shares)		1,793,975
Granted, weighted average exercise price, options (in dollars per share)		$ 0.07
Forfeited or expired, options (in shares)	(115,200)
Forfeited or expired, weighted average exercise price, options (in dollars per share)	$ 17.75
Outstanding, options (in shares)	3,384,275	3,499,475
Outstanding, weighted average exercise price, options (in dollars per share)	$ 0.64	$ 1.21
Exercisable, options (in shares)	2,191,281	1,299,394
Exercisable, weighted average exercise price, options (in dollars per share)	$ 1.69	$ 3.12

Note 8 - Stockholders' Equity53

Note 8 - Stockholders' Equity - Outstanding Stock Purchase Warrants (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Outstanding, shares (in shares)	32,751,578	56,442,157
Outstanding, weighted average exercise price (in dollars per share)	$ 0.07	$ 0.14
Exercised, shares (in shares)	(983,334)	21,884,420
Exercised, weighted average exercise price (in dollars per share)	$ 0.05	$ 0.06
Forfeited or expired, shares (in shares)	(1,112,001)	1,806,159
Forfeited or expired, weighted average exercise price (in dollars per share)	$ 0.57	$ 1
Outstanding, shares (in shares)	30,656,243	32,751,578
Outstanding, weighted average exercise price (in dollars per share)	$ 0.05	$ 0.07
Exercisable, shares (in shares)	30,656,243
Exercisable, weighted average exercise price (in dollars per share)	$ 0.05

Note 8 - Stockholders' Equity54

Note 8 - Stockholders' Equity - Common Stock Reserved for Future Issuance (Details) - shares	Mar. 31, 2017	Dec. 31, 2016
Common stock, reserved for future issuance (in shares)	92,895,777	95,106,312
Series B Convertible Preferred Stock [Member]
Common stock, reserved for future issuance (in shares)	285,714	285,714
Series C Convertible Preferred Stock [Member]
Common stock, reserved for future issuance (in shares)	57,363,520	57,363,520
Warrant [Member]
Common stock, reserved for future issuance (in shares)	30,656,243	32,751,578
Equity Incentive Plans [Member]
Common stock, reserved for future issuance (in shares)	4,590,300	4,705,500

Note 9 - Income Taxes (Details

Note 9 - Income Taxes (Details Textual) - USD ($)	12 Months Ended			186 Months Ended	189 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2016	Mar. 31, 2017
Income Tax Expense (Benefit)	$ 0	$ 0	$ 0	$ 0	$ 0

Note 10 - Government Grants a56

Note 10 - Government Grants and Contracts (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenue from Grants	$ 295,735	$ 47,600	$ 828,918	$ 428,081	$ 882,956
NIH Grants [Member]
Revenue from Grants	295,735	$ 47,600	828,918	$ 428,081	$ 882,956
Unused Grant Funds	$ 867,911		$ 505,487

Note 11 - Subsequent Events (De

Note 11 - Subsequent Events (Details Textual) - USD ($)	May 11, 2017	Apr. 30, 2017	Mar. 31, 2017	Mar. 23, 2017
Stock Issued During Period, Shares, Warrants Exercised			983,334
Proceeds from Warrant Exercises			$ 49,167
Subsequent Event [Member]
Stock Issued During Period, Shares, Warrants Exercised		2,500,000		983,334
Proceeds from Warrant Exercises		$ 100,000		$ 49,167
Subsequent Event [Member] | Series D Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues	1,000
Stock Issued During Period, Value, New Issues	$ 1,000,000
Convertible Preferred Stock, Shares Issued upon Conversion	66,666.67
Convertible Preferred Stock, Total Shares Issued upon Conversion	66,666,667

Note 2 - Summary of Significa58

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) shares in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Operating Leases, Future Minimum Payments Due	$ 113,995		$ 151,993
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	91.7	85.2	93.9	90.3	6.6
Minimum [Member]
Property, Plant and Equipment, Useful Life			3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life			5 years

Note 3 - Property and Equipme59

Note 3 - Property and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Depreciation, Depletion and Amortization, Nonproduction	$ 28,780	$ 28,935	$ 59,037

Note 3 - Property and Equipme60

Note 3 - Property and Equipment - Property and Equipment, Net (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Property and equipment, gross	$ 674,596	$ 670,246	$ 670,246
Accumulated depreciation and amortization	(622,316)	(615,418)	(586,638)
Property and equipment, net	52,280	54,828	83,608
Laboratory Equipment [Member]
Property and equipment, gross	530,306	525,956	525,956
Leasehold Improvements [Member]
Property and equipment, gross	115,605	115,605	115,605
Other Furniture Fixtures And Equipment [Member]
Property and equipment, gross	$ 28,685	$ 28,685	$ 28,685

Note 4 - Accrued Expenses - Sch

Note 4 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accrued salaries	$ 276,220	$ 201,170	$ 1,305
Accrued directors’ fees	105,769	78,070
Other	15,000	15,000	24,750
Total accrued expenses	$ 396,989	$ 294,240	$ 26,055

Note 5 - Government Grants an62

Note 5 - Government Grants and Contracts (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenue from Grants	$ 295,735	$ 47,600	$ 828,918	$ 428,081	$ 882,956
NIH Grants [Member]
Revenue from Grants	295,735	$ 47,600	828,918	$ 428,081	$ 882,956
Unused Grant Funds	$ 867,911		$ 505,487

Note 6 - Commitements (Details

Note 6 - Commitements (Details Textual)	12 Months Ended
	Dec. 31, 2016USD ($)ft²	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Mar. 31, 2017USD ($)ft²
Area of Real Estate Property | ft²	8,400			8,400
Operating Leases, Rent Expense	$ 149,288	$ 146,092	$ 117,084
Operating Leases, Future Minimum Payments Due	151,993			$ 113,995
Unrecorded Unconditional Purchase Obligation	$ 305,371			$ 225,159

Note 7 - Preferred Stock (Detai

Note 7 - Preferred Stock (Details Textual) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Feb. 28, 2015	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2014	Mar. 31, 2017	Dec. 31, 2015
Preferred Stock, Par or Stated Value Per Share			$ 0.01		$ 0.01	$ 0.01
Common Stock, Par or Stated Value Per Share			$ 0.001		0.001	0.001
Series A Convertible Preferred Stock [Member]
Common Stock, Par or Stated Value Per Share				$ 1,000
Preferred Stock, Shares Outstanding			0
Series B Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share			$ 1,000		$ 1,000	$ 1,000
Preferred Stock, Voting Rights			0
Preferred Stock, Shares Outstanding			100		100	100
Convertible Preferred Stock, Total Conversion Shares			285,714
Series C Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 1,000		$ 1,000		$ 1,000	$ 1,000
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants	$ 2,679,810
Stock Issued During Period, Value, New Issues	$ 983,941
Preferred Stock, Voting Rights			0
Conversion of Stock, Shares Converted		132
Preferred Stock, Shares Outstanding			2,868		2,868	3,000
Convertible Preferred Stock, Total Conversion Shares			57,363,520
Stock Issued During Period, Shares, New Issues	3,000
Warrants Issued in Connection with Series C Preferred Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	51,333,331
Adjustments to Additional Paid in Capital, Warrant Issued	$ 1,695,869
Conversion from Series A Convertible Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Converted				71
Conversion of Stock, Shares Issued				202,857
Conversion from Series B Convertible Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Converted				1,550
Conversion of Stock, Shares Issued				4,428,571
Conversion from Series C Convertible Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Converted			132
Conversion of Stock, Shares Issued			1,400,000

Note 8 - Common Stock (Details

Note 8 - Common Stock (Details Textual) - USD ($)	1 Months Ended		3 Months Ended		5 Months Ended	12 Months Ended
	Mar. 31, 2017	Oct. 31, 2014	Mar. 31, 2017	Mar. 31, 2016	Nov. 30, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Jun. 14, 2016	Jun. 13, 2016
Common Stock, Shares Authorized	300,000,000		300,000,000			300,000,000	150,000,000		300,000,000	150,000,000
Stock Issued During Period, Shares, Warrants Exercised	983,334
Proceeds from Warrant Exercises	$ 49,167
Common Stock, Capital Shares Reserved for Future Issuance	92,895,777		92,895,777			95,106,312
2006 Equity Incentive Plan [Member]
Allocated Share-based Compensation Expense			$ 14,580	$ 13,686		$ 54,805	$ 67,905	$ 101,191
Common Stock, Capital Shares Reserved for Future Issuance						1,705,500
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period						10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						3 years
2006 Equity Incentive Plan [Member] | Incentive Stock Options (ISO's) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent						110.00%
Equity Incentive Plan 2016 [Member]
Common Stock, Capital Shares Reserved for Future Issuance						3,000,000
Expense Associated with Warrant Modifications [Member]
Stock Issued During Period, Shares, Warrants Exercised		3,176,000				21,884,420
Proceeds from Warrant Exercises		$ 873,400				$ 1,339,801
Third Party Consulting Services [Member]
Stock Issued During Period, Shares, Issued for Services					378,205
Allocated Share-based Compensation Expense					$ 100,000

Note 8 - Common Stock - Convert

Note 8 - Common Stock - Convertible Stock Issued (Details) - shares	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Series A Convertible Preferred Stock [Member]
Conversions of Preferred Stock (in shares)		0	0	202,857
Series B Convertible Preferred Stock [Member]
Conversions of Preferred Stock (in shares)		0	0	4,428,571
Series C Convertible Preferred Stock [Member]
Conversions of Preferred Stock (in shares)	1,400,000	1,400,000	0	0

Note 8 - Common Stock - Activit

Note 8 - Common Stock - Activity of Stock Option Plan (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Outstanding, options (in shares)	3,499,475	1,705,500
Outstanding, weighted average exercise price, options (in dollars per share)	$ 1.21	$ 2.41
Outstanding, weighted average remaining contractual term, options (Year)		8 years 73 days
Outstanding, aggregate intrinsic value, options		$ 0
Exercisable, options (in shares)	2,191,281	1,299,394
Exercisable, weighted average exercise price, options (in dollars per share)	$ 1.69	$ 3.12
Exercisable, weighted average remaining contractual term, options (Year)		5 years 182 days
Granted, options (in shares)		1,793,975
Granted, weighted average exercise price, options (in dollars per share)		$ 0.07
Outstanding, options (in shares)	3,384,275	3,499,475
Exercisable, aggregate intrinsic value, options		$ 0
Outstanding, weighted average exercise price, options (in dollars per share)	$ 0.64	$ 1.21

Note 8 - Common Stock - Outstan

Note 8 - Common Stock - Outstanding Stock Purchase Warrants (Details) - $ / shares	Mar. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Weighted Average Exercise Price (in dollars per share)	$ 0.05	$ 0.07	$ 0.14
Number of Shares (in shares)	30,656,243	32,751,578	56,442,157
Number of Shares (in shares)		32,751,578
Weighted Average Exercise Price (in dollars per share)		$ 0.07
Warrants Expiration 2 [Member]
Weighted Average Exercise Price (in dollars per share)		$ 1
Number of Shares (in shares)		45,000
Warrants Expiration 3 [Member]
Weighted Average Exercise Price (in dollars per share)		$ 1
Number of Shares (in shares)		567,001
Warrants Expiration 4 [Member]
Weighted Average Exercise Price (in dollars per share)		$ 0.05
Number of Shares (in shares)		1,483,334
Warrants Expiration 1[Member]
Weighted Average Exercise Price (in dollars per share)		$ 0.05
Number of Shares (in shares)		30,656,243

Note 8 - Common Stock - Activ69

Note 8 - Common Stock - Activity of Stock Purchase Warrants (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Outstanding, shares (in shares)	32,751,578	56,442,157
Outstanding, weighted average exercise price (in dollars per share)	$ 0.07	$ 0.14
Exercised, shares (in shares)	983,334	(21,884,420)
Exercised, weighted average exercise price (in dollars per share)	$ 0.05	$ 0.06
Forfeited or expired, shares (in shares)	1,112,001	(1,806,159)
Forfeited or expired, weighted average exercise price (in dollars per share)	$ 0.57	$ 1
Outstanding, shares (in shares)	30,656,243	32,751,578
Outstanding, weighted average exercise price (in dollars per share)	$ 0.05	$ 0.07

Note 8 - Common Stock - Common

Note 8 - Common Stock - Common Stock Reserved for Future Issuance (Details) - shares	Mar. 31, 2017	Dec. 31, 2016
Common stock, reserved for future issuance (in shares)	92,895,777	95,106,312
Warrant [Member]
Common stock, reserved for future issuance (in shares)	30,656,243	32,751,578
Equity Incentive Plans [Member]
Common stock, reserved for future issuance (in shares)	4,590,300	4,705,500
Series B Convertible Preferred Stock [Member]
Common stock, reserved for future issuance (in shares)	285,714	285,714
Series C Convertible Preferred Stock [Member]
Common stock, reserved for future issuance (in shares)	57,363,520	57,363,520

Note 9 - Stock-based Compensa71

Note 9 - Stock-based Compensation (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
General and Administrative Expense	$ 292,667	$ 906,505	$ 2,131,426	$ 1,429,731	$ 1,807,605
Third Party Consulting Services [Member]
Allocated Share-based Compensation Expense				100,000
Expense Associated with Warrant Modifications [Member]
General and Administrative Expense		469,799	912,862	0	277,912
2006 Equity Incentive Plan [Member]
Allocated Share-based Compensation Expense	14,580	$ 13,686	54,805	$ 67,905	$ 101,191
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 117,404		$ 132,032
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 109 days		2 years 182 days

Note 9 - Stock-Based Compensa72

Note 9 - Stock-Based Compensation - Significant Assumption Used in Fair Value Calculation (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Weighted average risk-free interest rates	2.26%	1.99%	1.98%
Expected dividend yield	0.00%	0.00%	0.00%
Expected life of option (yrs) (Year)	7 years	7 years	7 years
Expected volatility	88.72%	91.43%	94.88%

Note 9 - Stock-Based Compensa73

Note 9 - Stock-Based Compensation - Allocation of Stock Option Expense (Details) - Employee Stock Option [Member] - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Allocated stock option expense	$ 54,805	$ 67,905	$ 101,191
General and Administrative Expense [Member]
Allocated stock option expense	31,191	45,822	69,057
Research and Development Expense [Member]
Allocated stock option expense	$ 23,614	$ 22,083	$ 32,134

Note 9 - Stock-Based Compensa74

Note 9 - Stock-Based Compensation - Additional Information for Stock Options (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Weighted average fair value of options granted (in dollars per share)	$ 0.05	$ 0.09	$ 0.14
Intrinsic value of options exercised	$ 0	$ 0	$ 0
Total fair value of options vested	$ 54,757	$ 66,622	$ 97,707

Note 10 - Retirement Plan (Deta

Note 10 - Retirement Plan (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 33,871	$ 40,296	$ 35,567

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details Textual) - USD ($)	12 Months Ended			186 Months Ended	189 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2016	Mar. 31, 2017
Income Tax Expense (Benefit)	$ 0	$ 0	$ 0	$ 0	$ 0
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	892,000			892,000
Domestic Tax Authority [Member]
Operating Loss Carryforwards	$ 69,500,000			$ 69,500,000

Note 11 - Income Taxes - Deferr

Note 11 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Net operating loss carryforward	$ 24,689,298	$ 23,822,431
Research and development tax credit carryforward	892,231	893,797
Stock-based compensation expense	2,748,899	2,419,892
Depreciation	1,331
Total deferred tax assets	28,331,759	27,136,120
Deferred tax liabilities
Depreciation		(5,086)
Total deferred tax liabilities		(5,086)
Net deferred tax assets	28,331,759	27,131,034
Valuation allowance	(28,331,759)	(27,131,034)
	$ 0	$ 0

Note 11 - Income Taxes - Reconc

Note 11 - Income Taxes - Reconciliation of Income Tax Benefit (Details) - USD ($)	12 Months Ended			186 Months Ended	189 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2016	Mar. 31, 2017
U.S. federal statutory rate applied to pretax loss	$ (1,112,378)	$ (936,936)	$ (906,830)
Permanent differences	2,012	2,914	1,734
Research and development credits	59,087	67,901	26,648
Change in valuation allowance	1,051,279	866,121	878,448
Reported income tax expense	$ 0	$ 0	$ 0	$ 0	$ 0

Note 12 - Subsequent Event (Det

Note 12 - Subsequent Event (Details Textual) - USD ($)	1 Months Ended
	Apr. 30, 2017	Mar. 31, 2017	Mar. 23, 2017
Stock Issued During Period, Shares, Warrants Exercised		983,334
Proceeds from Warrant Exercises		$ 49,167
Subsequent Event [Member]
Stock Issued During Period, Shares, Warrants Exercised	2,500,000		983,334
Proceeds from Warrant Exercises	$ 100,000		$ 49,167

Schedule II - Valuation and Q80

Schedule II - Valuation and Qualifying Accounts - Valuation and Qualifying Accounts (Details) - Valuation Allowance of Deferred Tax Assets [Member] - USD ($)		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Balance at End Of Period		$ 28,331,759	$ 27,131,034	$ 26,021,943
Balance at Beginning Of Period		27,131,034	26,021,943	25,002,881
Additions Charged to Costs and Expenses		1,200,725	1,109,091	1,019,062
Additions Charged to Other Accounts		0	0	0
Deductions	[1]	$ 0	$ 0	$ 0
[1]	Deductions represent the effect of expiring NOL carryforwards from prior year.